Functionally Enhanced Placenta-Derived Mesenchymal Stem Cells Inhibit Adipogenesis in Orbital Fibroblasts With Graves’ Ophthalmopathy

    August 2020 in “ Research Square (Research Square) ”
    Jae Yeon Kim, Sohae Park, Hyunjung Lee, Helen Lew, Gi Jin Kim
    Studysummary This study found that PD-MSCs overexpressing PRL-1 inhibited adipogenesis in orbital fibroblasts from Graves' ophthalmopathy patients, potentially offering a new therapeutic approach for degenerative diseases. Our plain-language summary of this paper — not a Tressless recommendation.
    The study investigated the effects of PRL-1-overexpressing placenta-derived mesenchymal stem cells (PD-MSCs PRL-1) on adipogenesis in orbital fibroblasts (OFs) from patients with Graves’ ophthalmopathy (GO). The research found that PD-MSCs PRL-1 significantly reduced lipid accumulation and decreased the expression of adipogenic markers in OFs compared to naïve cells. This effect was linked to the secretion of insulin-like growth factor-binding proteins (IGFBPs) by PD-MSCs PRL-1, which downregulated the PI3K/AKT/mTOR signaling pathway and upregulated phosphorylated FAK through integrin interactions. These findings suggested that functionally enhanced PD-MSCs could offer a novel therapeutic approach for treating degenerative diseases like GO.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results